Eton Pharmaceutcials

ETON

Market cap $473M

Overview Fund Activity

17.65 USD

+0.08

0.46%

At close Updated Sep 12, 4:00 PM EDT

1 day

0.46%

5 days

-0.11%

1 month

1.91%

3 months

21.64%

6 months

19.42%

Year to date

23.34%

1 year

266.18%

5 years

111.63%

10 years

182.4%

About: Eton Pharmaceuticals Inc is a United States based specialty pharmaceutical company. The company is engaged in developing and commercializing pharmaceutical products to fulfill an unmet patient need. It has four commercial rare disease products, Alkindi Sprinkle for the treatment of adrenocortical insufficiency; Carglumic Acid for the treatment of hyperammonemia, Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of hereditary tyrosinemia type 1 (HT-1). The Company has three additional product candidates in late-stage development: ET-400, ET-600, and ZENEO hydrocortisone autoinjector.

Employees: 31

Healthcare Drug Manufacturers - Specialty & Generic

0

Funds holding %

of 7,462 funds

–

Analysts bullish %

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

2,574% more call options, than puts

Call options by funds: $4.55M | Put options by funds: $170K

84% more repeat investments, than reductions

Existing positions increased: 35 | Existing positions reduced: 19

29% more capital invested

Capital invested by funds: $183M [Q1] → $236M (+$52.5M) [Q2]

9.05% more ownership

Funds ownership: 52.66% [Q1] → 61.71% (+9.05%) [Q2]

0% more funds holding in top 10

Funds holding in top 10: 1 [Q1] → 1 (+0) [Q2]

4% less first-time investments, than exits

New positions opened: 24 | Existing positions closed: 25

1% less funds holding

Funds holding: 85 [Q1] → 84 (-1) [Q2]

See Fund Rankings

Financial journalist opinion

Eton Pharmaceuticals to Participate at 2025 Wells Fargo Healthcare Conference

DEER PARK, Ill., Aug. 20, 2025 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that members of the Company's executive leadership team will host 1x1 meetings at the 2025 Wells Fargo Healthcare Conference being held September 3-5, 2025 in Boston, MA.

Eton Pharmaceuticals to Participate at 2025 Wells Fargo Healthcare Conference

Eton Pharmaceuticals, Inc. (ETON) Q2 2025 Earnings Call Transcript

Eton Pharmaceuticals, Inc. (NASDAQ:ETON ) Q2 2025 Earnings Conference Call August 7, 2025 4:30 PM ET Company Participants David C. Krempa - Chief Business Officer James R.

Eton Pharmaceuticals, Inc. (ETON) Q2 2025 Earnings Call Transcript

Eton Pharmaceuticals: Growth At A Reasonable Price, Or Maybe Even Better With Options

Eton Pharmaceuticals offers GARP potential, focusing on ultra-rare disease drugs acquired at low cost, with a lean, specialized sales force and positive cash flow. My DCF model shows 80%-87% upside to fair value ($26.17) in the base case, with even higher potential in optimistic scenarios. Risks include pipeline failures and US drug price pressures, but even pessimistic scenarios suggest current valuation is fair, limiting downside.

Eton Pharmaceuticals: Growth At A Reasonable Price, Or Maybe Even Better With Options

Zacks Investment Research

Eton Pharmaceuticals, Inc. (ETON) Reports Q2 Loss, Tops Revenue Estimates

Eton Pharmaceuticals, Inc. (ETON) came out with a quarterly loss of $0.1 per share versus the Zacks Consensus Estimate of a loss of $0.01. This compares to a loss of $0.12 per share a year ago.

Eton Pharmaceuticals, Inc. (ETON) Reports Q2 Loss, Tops Revenue Estimates

The Motley Fool

Eton (ETON) Q2 Revenue Jumps 108%

Eton Pharmaceuticals (ETON), a biopharmaceutical company focused on rare diseases, posted earnings for Q2 2025 on August 7, 2025. The main highlight was a strong revenue increase from both core and recently acquired products.

Eton (ETON) Q2 Revenue Jumps 108%

Eton Pharmaceuticals Reports Second Quarter 2025 Financial Results

Q2 2025 product sales of $18.9 million, representing 108% growth over Q2 2024 and the 18th straight quarter of sequential product sales growth Q2 2025 basic and fully diluted GAAP EPS of $(0.10), non-GAAP fully diluted EPS of $0.03, and Adjusted EBITDA of $3.1 million Launched KHINDIVI™ (hydrocortisone) Oral Solution Reached 100 active INCRELEX® patients, ahead of previous guidance of year end Company projects reaching an annual revenue run rate of $80 million in Q3, one quarter ahead of previous guidance Management to hold conference call today at 4:30pm ET DEER PARK, Ill., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or “the Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today reported financial results for the quarter ended June 30, 2025.

Eton Pharmaceuticals Reports Second Quarter 2025 Financial Results

Zacks Investment Research

Eton Pharmaceuticals, Inc. (ETON) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

Eton Pharmaceuticals (ETON) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Eton Pharmaceuticals, Inc. (ETON) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

Eton Pharmaceuticals to Report Second Quarter 2025 Financial Results on Thursday, August 7, 2025

DEER PARK, Ill., July 28, 2025 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that it will report second quarter 2025 financial results on Thursday, August 7, 2025. Management will host a conference call and live audio webcast to discuss the results at 4:30 p.m. ET (3:30 p.m. CT).

Eton Pharmaceuticals to Report Second Quarter 2025 Financial Results on Thursday, August 7, 2025

Eton Pharma Near Term Catalysts Vanish

Important near-term catalysts for ETON have been eliminated due to insider stock sales and a disappointing partial FDA approval for their new drug, Khindivi. Insider sales by the CEO and CBO after Q1 2025 earnings suggest no imminent M&A activity and have dented investor confidence. Khindivi's FDA approval excluded the key under-5 age group, removing the potential for a Khindivi driven near-term revenue guidance beat.

Eton Pharma Near Term Catalysts Vanish

Eton Pharmaceuticals Announces FDA Acceptance of New Drug Application for ET-600 (Desmopressin Oral Solution)

- NDA assigned a Target Action Date of February 25, 2026 -- Product has patent protection through 2044 - DEER PARK, Ill., July 08, 2025 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced the Company's New Drug Application (NDA) for ET-600, a proprietary patented formulation of desmopressin oral solution, has been accepted for review by the U.S. Food and Drug Administration (FDA) and has been assigned a Prescription Drug User Fee Act (PDUFA) target action date of February 25, 2026.

Eton Pharmaceuticals Announces FDA Acceptance of New Drug Application for ET-600 (Desmopressin Oral Solution)

See News Rankings

Charts implemented using Lightweight Charts™